Equities

Trinity Biotech PLC

Trinity Biotech PLC

Actions
  • Price (USD)1.69
  • Today's Change-0.04 / -2.31%
  • Shares traded19.95k
  • 1 Year change-67.02%
  • Beta1.1941
Data delayed at least 15 minutes, as of May 07 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic systems, including both reagents and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ. The Company manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.

  • Revenue in USD (TTM)56.83m
  • Net income in USD-36.87m
  • Incorporated1992
  • Employees398.00
  • Location
    Trinity Biotech PLCIda Business ParkBray, Co Wicklow, IrelandBRAY 18IrelandIRL
  • Phone+353 12769800
  • Fax+353 12769888
  • Websitehttps://www.trinitybiotech.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
TRIB:NSQ since
announced
Transaction
value
Waveform Technologies Inc-Continuous Glucose Monitoring AssetsAnnounced31 Jan 202431 Jan 2024Announced-22.12%21.50m
Data delayed at least 15 minutes, as of May 07 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Allied Corp21.51k-9.00m15.34m--------713.32-0.0915-0.09150.0002-0.07110.00511.650.1441---214.39-------6,919.57---41,861.41--0.0333-31.86-----56.46--31.30------
Cardio Diagnostics Holdings Inc17.07k-8.38m15.80m7.00--5.08--925.88-0.7363-0.73630.00140.1440.0032--6.882,438.57-156.40---211.46-------49,073.46-----5.450.1122--1,696.84---79.72------
Traws Pharma Inc226.00k-18.95m16.22m16.00--1.26--71.76-0.9029-0.90290.01080.50810.0073--9.6214,125.00-61.07-63.43-84.61-85.72-----8,384.07-3,257.92----0.00--0.00-28.720.0844------
Minerva Neurosciences Inc0.00-31.60m16.36m9.00---------4.48-4.480.00-5.230.00----0.00-61.90-49.89-65.32-52.39-------442.65------------6.55------
Trinity Biotech plc (ADR)56.83m-36.87m16.38m398.00------0.2881-17.71-9.3112.36-15.670.75011.763.83---48.66-19.82-61.89-28.8434.2239.90-64.88-28.301.27-1.611.77---9.10-10.1515.41---31.08--
Cocrystal Pharma Inc0.00-17.98m16.38m12.00--0.6208-----1.90-1.900.002.590.00----0.00-49.89-50.94-53.19-52.77-------1,501.78----0.00------53.69--33.34--
Tonix Pharmaceuticals Holding Corp7.77m-116.66m16.39m103.00--0.1078--2.11-8.62-8.620.45721.800.0409----75,417.48-61.38-59.46-68.01-65.9238.97---1,501.78-5,126.731.81--0.0779------0.1874--320.57--
Vaxxinity Inc0.00-56.94m16.48m57.00--1.23-----0.4499-0.44990.000.10580.00----0.00-75.56---111.46--------------0.5308------24.31------
NanoViricides Inc0.00-9.36m16.49m7.00--1.42-----0.8004-0.80040.000.98280.00----0.00-55.47-43.54-57.90-46.29------------0.00-------5.94---8.90--
Solarwindow Technologies Inc0.00-2.36m16.49m1.00--2.55-----0.0443-0.04680.000.12140.00----0.00-25.51-44.62-26.29-45.23------------0.00------44.04------
Talis Biomedical Corp2.13m-62.01m16.69m99.00--0.2415--7.82-34.26-34.261.1837.930.0162--11.9221,555.55-46.98-68.18-51.14-74.2298.08---2,905.67-1,615.96----0.00---55.65-2.2445.13---1.83--
Nascent Biotech Inc0.00-2.09m16.94m----554.47-----0.0147-0.01470.000.00020.00-------346.80-815.53-----------548.75----0.8045---100.00---495.46------
Aytu Biopharma Inc98.50m-18.00m17.04m150.00--0.5186--0.173-4.06-4.0620.975.900.72242.793.59656,653.30-13.20-33.56-25.46-52.8163.2456.89-18.27-73.810.9094-0.43820.3281--11.1096.5684.33------
Ibio Inc50.00k-20.77m17.14m26.00--0.7019--342.74-21.91-27.300.04372.840.0012--0.01291,923.08-48.41-28.09-113.84-32.63-----41,546.00-1,467.30---518.330.5942---100.00--0.9764--42.90--
VBI Vaccines Inc8.68m-93.84m17.21m131.00--1.91--1.98-9.42-9.420.55880.31470.07171.66184.7266,274.81-76.71-46.58-143.53-58.62-44.09-277.46-1,069.29-2,755.980.3662-4.280.8709--702.4020.9417.18---32.07--
Indaptus Therapeutics Inc0.00-15.42m17.33m7.00--1.41-----1.84-1.840.001.440.00----0.00-71.76-66.55-83.87-81.23------------0.00-------7.68------
Data as of May 07 2024. Currency figures normalised to Trinity Biotech PLC's reporting currency: US Dollar USD

Institutional shareholders

50.82%Per cent of shares held by top holders
HolderShares% Held
Perceptive Advisors LLCas of 30 Apr 20242.72m35.60%
Hunter Associates Investment Management LLCas of 31 Mar 2024317.81k4.16%
Stonehill Capital Management LLCas of 31 Dec 2023302.60k3.96%
Renaissance Technologies LLCas of 31 Dec 2023270.78k3.54%
Acadian Asset Management LLCas of 31 Dec 2023136.98k1.79%
Whitefort Capital Management, LPas of 31 Dec 202381.90k1.07%
Cambridge Investment Research Advisors, Inc.as of 31 Mar 202422.28k0.29%
Becker Capital Management, Inc.as of 31 Dec 202318.00k0.24%
Citadel Securities LLCas of 31 Dec 20236.50k0.09%
WealthSource Partners LLCas of 31 Dec 20236.04k0.08%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.